# Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis

> **NCT00991861** · PHASE2 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 100 (estimated)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** LAS41007 o.d.
- **DRUG:** LAS41007 b.i.d.
- **DRUG:** LAS106521

## Key facts

- **NCT ID:** NCT00991861
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2015-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00991861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00991861, "Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00991861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*